252 related articles for article (PubMed ID: 26659543)
1. Pharmacokinetics and pharmacodynamics of γ-hydroxybutyrate in healthy subjects.
Liechti ME; Quednow BB; Liakoni E; Dornbierer D; von Rotz R; Gachet MS; Gertsch J; Seifritz E; Bosch OG
Br J Clin Pharmacol; 2016 May; 81(5):980-8. PubMed ID: 26659543
[TBL] [Abstract][Full Text] [Related]
2. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics.
Abanades S; Farré M; Segura M; Pichini S; Barral D; Pacifici R; Pellegrini M; Fonseca F; Langohr K; De La Torre R
Ann N Y Acad Sci; 2006 Aug; 1074():559-76. PubMed ID: 17105953
[TBL] [Abstract][Full Text] [Related]
3. Cataleptic effects of gamma-hydroxybutyrate (GHB), its precursor gamma-butyrolactone (GBL), and GABAB receptor agonists in mice: differential antagonism by the GABAB receptor antagonist CGP35348.
Koek W; Mercer SL; Coop A
Psychopharmacology (Berl); 2007 Jun; 192(3):407-14. PubMed ID: 17277933
[TBL] [Abstract][Full Text] [Related]
4. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome.
Busardò FP; Jones AW
Curr Neuropharmacol; 2015 Jan; 13(1):47-70. PubMed ID: 26074743
[TBL] [Abstract][Full Text] [Related]
5. γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology.
Felmlee MA; Morse BL; Morris ME
AAPS J; 2021 Jan; 23(1):22. PubMed ID: 33417072
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients.
Scharf MB; Lai AA; Branigan B; Stover R; Berkowitz DB
Sleep; 1998 Aug; 21(5):507-14. PubMed ID: 9703591
[TBL] [Abstract][Full Text] [Related]
7. The gamma-hydroxybutyrate withdrawal syndrome.
Tarabar AF; Nelson LS
Toxicol Rev; 2004; 23(1):45-9. PubMed ID: 15298492
[TBL] [Abstract][Full Text] [Related]
8. Gamma-hydroxybutyrate and ethanol effects and interactions in humans.
Thai D; Dyer JE; Benowitz NL; Haller CA
J Clin Psychopharmacol; 2006 Oct; 26(5):524-9. PubMed ID: 16974199
[TBL] [Abstract][Full Text] [Related]
9. Alterations in neuronal transport but not blood-brain barrier transport are observed during gamma-hydroxybutyrate (GHB) sedative/hypnotic tolerance.
Bhattacharya I; Raybon JJ; Boje KM
Pharm Res; 2006 Sep; 23(9):2067-77. PubMed ID: 16952000
[TBL] [Abstract][Full Text] [Related]
10. Ultra-high-performance liquid chromatography tandem mass spectrometry determination of GHB, GHB-glucuronide in plasma and cerebrospinal fluid of narcoleptic patients under sodium oxybate treatment.
Tittarelli R; Pichini S; Pedersen DS; Pacifici R; Moresco M; Pizza F; Busardò FP; Plazzi G
Forensic Sci Int; 2017 May; 274():70-74. PubMed ID: 28139340
[TBL] [Abstract][Full Text] [Related]
11. Sedative and hypothermic effects of gamma-hydroxybutyrate (GHB) in rats alone and in combination with other drugs: assessment using biotelemetry.
van Nieuwenhuijzen PS; McGregor IS
Drug Alcohol Depend; 2009 Aug; 103(3):137-47. PubMed ID: 19446408
[TBL] [Abstract][Full Text] [Related]
12. Tolerance to the hypnotic and electroencephalographic effect of gamma-hydroxybutyrate in the rat: pharmacokinetic and pharmacodynamic aspects.
Van Sassenbroeck DK; De Paepe P; Belpaire FM; Boon PA; Buylaert WA
J Pharm Pharmacol; 2003 May; 55(5):609-15. PubMed ID: 12831503
[TBL] [Abstract][Full Text] [Related]
13. Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome.
Busardò FP; Kyriakou C; Napoletano S; Marinelli E; Zaami S
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4654-63. PubMed ID: 26698265
[TBL] [Abstract][Full Text] [Related]
14. The distribution of gamma-hydroxybutyrate-induced Fos expression in rat brain: comparison with baclofen.
van Nieuwenhuijzen PS; McGregor IS; Hunt GE
Neuroscience; 2009 Jan; 158(2):441-55. PubMed ID: 18996447
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects.
Brenneisen R; Elsohly MA; Murphy TP; Passarelli J; Russmann S; Salamone SJ; Watson DE
J Anal Toxicol; 2004; 28(8):625-30. PubMed ID: 15538955
[TBL] [Abstract][Full Text] [Related]
16. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms.
J Toxicol Clin Toxicol; 2003; 41(2):131-5. PubMed ID: 12733850
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients.
Borgen LA; Okerholm RA; Lai A; Scharf MB
J Clin Pharmacol; 2004 Mar; 44(3):253-7. PubMed ID: 14973300
[TBL] [Abstract][Full Text] [Related]
18. Sodium Oxybate Therapy for Alcohol Withdrawal Syndrome and Keeping of Alcohol Abstinence.
Mannucci C; Pichini S; Spagnolo EV; Calapai F; Gangemi S; Navarra M; Calapai G
Curr Drug Metab; 2018; 19(13):1056-1064. PubMed ID: 29219048
[TBL] [Abstract][Full Text] [Related]
19. The motor-impairing effects of GABA(A) and GABA(B) agonists in gamma-hydroxybutyrate (GHB)-treated rats: cross-tolerance to baclofen but not flunitrazepam.
Smith MA; Gergans SR; Lyle MA
Eur J Pharmacol; 2006 Dec; 552(1-3):83-9. PubMed ID: 17026996
[TBL] [Abstract][Full Text] [Related]
20. Effect of γ-hydroxybutyrate (GHB) on driving as measured by a driving simulator.
Liakoni E; Dempsey DA; Meyers M; Murphy NG; Fiorentino D; Havel C; Haller C; Benowitz NL
Psychopharmacology (Berl); 2018 Nov; 235(11):3223-3232. PubMed ID: 30232528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
